お勉強334:腎明細胞がんもセラノティクスの時代が来る？
ASCOGU2023 さらに続き
Exciting data from ZIRCON presented by @KidneyCancerDoc; TLX250-CDx PET/CT is well tolerated and can accurately and noninvasively identify ccRCC - Look forward to future studies and uses @OncLive pic.twitter.com/xek9NOPH3L
— Bradley McGregor (@BradMcG04) February 18, 2023
https://twitter.com/_ShankarSiva/status/1627070039131291649
@ASCO #GU23 Zr-89 girentuximab ZIRCON trial of n=332. Approx 93% positive predictive value for clear cell kidney cancer in primary masses <7cm. Sensitive also in subgroup <4cm. A new ‘molecular biopsy’ option for #kidneycancer? #radonc #kcsm pic.twitter.com/7aOCxYmI9y
— Shankar Siva (@_ShankarSiva) February 18, 2023
https://twitter.com/zklaassen_md/status/1627075466317406213
Exciting data from the Ph 3 ZIRCON trial @KidneyCancerDoc
— Zach Klaassen (@zklaassen_md) February 18, 2023
For me, secondary endpoint of sensitivity/specificity in cT1a masses most clinically meaningful: 3 cm SRM deciding between robo PNx vs biopsy vs cryo vs AS#GU23 @urotoday https://t.co/uqFBbELzIo pic.twitter.com/QWqXstk9Z9
https://twitter.com/zklaassen_md/status/1627006307503939587
LBA presented @ 14:00 PST #GU23 @urotoday
— Zach Klaassen (@zklaassen_md) February 18, 2023
ZIRCON - Ph 3 study of 89Zr-DFO-girentuximab for PET/CT imaging of ccRCC (n=284)
📌 Prim Obj - Sensitivity for ccRCC in indeterminate RMs: 86% (95%CI 80-90); Specificity: 87% (95%CI 79-92)
📌 Sec Obj - Sensitivity for ccRCC in cT1a… pic.twitter.com/CZK5b7MXaO
腎がんに対する新規画像診断
陽性/陰性的中率とかを見ると、結構いい感じ？
（clear cellかどうか鑑別するという意義もあるよう）
ccRCCで高発現する酵素である
炭酸脱水酵素IX（CAIX）を標的とする抗体製剤のようです
当然、セラノティクスの流れが期待され、
実際一相試験とかは始まっているようです。